Home › Compare › JXHGF vs ABBV
JXHGF yields 2.56% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, JXHGF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JXHGF + ABBV for your $10,000?
ENEOS Holdings, Inc., through its subsidiaries, engages in the energy, oil and natural gas exploration and production (E&P), and metals businesses Japan, China, and internationally. The company operates through Energy, Oil and Natural Gas E&P, Metals, and Other segments. It manufactures and sells petroleum products, including gasoline, kerosene, lubricants, etc., as well as petrochemicals; and offers crude oil, natural gas, and copper concentrates. In addition, the company offers non-ferrous metal products, including electrolytic coppers, functional materials, and thin-film materials. Further, the company develops and explores non-ferrous metal resources and products; recycles industrial waste treatment, titanium, and electric wires. Additionally, the company offers copper foils, precision rolled, and precision-fabricated products. Furthermore, it engages in the asphalt paving, civil engineering, construction, land transportation, and real estate leasing business. It is engaged in the sales of mineral resources; and researching, studying, evaluating, designing and planning, and consulting services. ENEOS Holdings, Inc. was founded in 1888 and is headquartered in Tokyo, Japan.
Full JXHGF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.